SCHEMBL1017444

SCHEMBL1017444

C=CCc1ccn[c]n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7006247 0.71
SCHEMBL4926718 0.71
SCHEMBL533497 0.71
SCHEMBL467077 0.68
SCHEMBL1199660 0.67
SCHEMBL1476980 0.67 HPGD (0.34)
SCHEMBL1477525 0.67
SCHEMBL7588160 0.67
SCHEMBL3959069 0.67
SCHEMBL17103337 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3474845-B1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX INC (US) 2024-03-20 EP claimed
EP-3664793-B1 MACROCYCLIC IMMUNOMODULATORS CHEMOCENTRYX INC (US) 2022-06-29 EP claimed
CN-112752755-A Heterocyclyl compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2021-05-04 CN claimed
EP-3664793-A1 MACROCYCLIC IMMUNOMODULATORS ChemoCentryx, Inc. (US) 2020-06-17 EP claimed
EP-3474845-A1 IMMUNOMODULATOR COMPOUNDS ChemoCentryx, Inc. (US) 2019-05-01 EP claimed
US-20190048022-A1 MACROCYCLIC IMMUNOMODULATORS CHEMOCENTRYX, INC. 2019-02-14 US claimed
WO-2019032547-A1 MACROCYCLIC IMMUNOMODULATORS CHEMOCENTRYX, INC. (US) 2019-02-14 WO claimed
US-20180008554-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. 2018-01-11 US claimed
WO-2018005374-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. (US) 2018-01-04 WO claimed
EP-2651930-B1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INT (DE) 2015-10-28 EP claimed
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-02-19 US claimed
EP-1951678-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-06 EP claimed
WO-2008065068-A2 SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS NOVARTIS AG (CH) 2008-06-05 WO claimed
WO-2007046550-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO claimed
US-6969728-B2 Antiinflammatory agents GENZYME CORPORATION (US) 2005-11-29 US claimed
US-6576628-B1 Matrix metalloprotease inhibitors; arthritis, corneal ulcers, arteriosclerosis ROCHE DIAGNOSTICS GMBH (DE) 2003-06-10 US claimed
US-4843078-A ANXIOLYTIC AGENTS SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) 1989-06-27 US claimed
EP-0014322-B1 POLYCARBONATE COMPOSITION CONTAINING A METAL SALT OF AN AROMATIC SULFONAMIDE AS AN IGNITION DEPRESSANT THE DOW CHEMICAL COMPANY (US) 1983-01-12 EP claimed
US-4254015-A Polycarbonate containing an aromatic sulfonamide as an ignition depressant THE DOW CHEMICAL COMPANY (US) 1981-03-03 US claimed
EP-0014322-A1 Polycarbonate composition containing a metal salt of an aromatic sulfonamide as an ignition depressant THE DOW CHEMICAL COMPANY (US) 1980-08-20 EP claimed